3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
625
pembrolizumab
606
Magnetic Resonance Spectroscopy
550
Carboplatin
448
Cisplatin
396
Cyclophosphamide
394
Biopsy
371
Paclitaxel
323
Nivolumab
322
Gemcitabine
317
Radiotherapy
283
Bevacizumab
242
Dexamethasone
222
fludarabine
213
Docetaxel
198
durvalumab
194
Oxaliplatin
187
venetoclax
186
atezolizumab
179
Fluorouracil
176
Rituximab
175
Pemetrexed
172
Capecitabine
167
Radiation
164
Doxorubicin
164
Radiosurgery
159
Ipilimumab
145
Etoposide
142
Leucovorin
140
Lenalidomide
138
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
N(4)-oleylcytosine arabinoside
×
90 days
×
Clear all
NCT05498428
2026-05-08
PALOMA-2
Janssen Research & Development, LLC
Phase 2
Recruiting
520 enrolled
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled